Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 1

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 1
---
 of October 28, 2025, the aggregate market value
of our outstanding common stock held by non-affiliates was $8,895,663 based on 1,166,441 shares of outstanding common stock, of which
1,095,525 shares are held by non-affiliates, and the last reported sale price of our common stock of $8.12 per share on October 13, 2025.
Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding
more than one-third of our public float in any 12-month period so long as our public float remains below $75,000,000. As of the date of
this prospectus, we have sold securities with an aggregate market value of $1,188,639 pursuant to General Instruction 1.B.6 of Form S-3
during the 12-calendar month period that ends on and includes the date hereof.

INVESTING IN OUR SECURITIES INVOLVES RISKS.
YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES DESCRIBED UNDER THE HEADING“RISK FACTORS” CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS, AND UNDER SIMILAR HEADINGS IN OTHER DOCUMENTS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS OR ANY SUCH PROSPECTUS SUPPLEMENT. SEE“RISK FACTORS”
ON PAGE S-9 OF THIS PROSPECTUS SUPPLEMENT.

Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.

<div align='center'>Lucid Capital Markets

The date of this prospectus supplement is October
29, 2025.

Table of Contents</div>

| Prospectus Supplement               | Page |
| ABOUT THIS PROSPECTUS SUPPLEMENT    | S-1  |
| FORWARD-LOOKING STATEMENTS          | S-2  |
| THE COMPANY                         | S-4  |
| THE OFFERING                        | S-8  |
| RISK FACTORS                        | S-9  |
| USE OF PROCEEDS                     | S-19 |
| DIVIDEND POLICY                     | S-19 |
| DILUTION